What are you looking for?

Need help finding what you are looking for? Contact Us

Compare

Free Samples

Home Market Research Reports Pharmaceutical

Clinical Trial

PUBLISHER: Market Research Future | PRODUCT CODE: 1702334

PUBLISHER: Market Research Future | PRODUCT CODE: 1702334

Global Xerosis Market Information by Treatment (emollients, moisturizer, humidifier, oils, others) by Causes (eczema, psoriasis, diabetes, hypothyroidism, aging, others) by End Users (hospitals, dermatology clinics, home care) Forecast till 2032

PUBLISHED: February 28, 2025

PAGES: 188 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

The Xerosis Market is expected to develop at a compound annual growth rate (CAGR) of 7.71% from 2024 to 2032. Xerosis, also known as xeroderma, is a skin disorder characterized by excessive dryness caused by over-cleansing, excessive showering, living in low-humidity areas, dehydration, prolonged sun exposure, ageing, and so on. Xerosis most typically affects the scalp, lower legs, arms, and thighs, with symptoms including scaling (visible peeling of the outer skin layer), itching, and skin cracking. Other symptoms include dry, itchy, and scaly skin, flaky skin, and irritated red skin. Xerosis is common throughout the winter because the cold, dry air causes the skin to lose moisture. Xerosis can also be caused by a vitamin A or vitamin D deficiency, systemic disease, or drug adverse effects. The conventional treatment for xerosis is to apply emollients, moisturizers, and so on.

Xerosis also responds favorable to lifestyle adjustments. Hormonal changes caused by aging, diabetes, and other conditions alter sweat and sebaceous glands, increasing the risk of Xerosis. Petrolatum, vegetable oils, mineral oil, and other highly occlusive skin barrier products produce good outcomes. Lanolin, a natural lipid obtained from sheep's wool, replaces the lipids found in human skin and is one of the most successful therapies for xeroderma. The main disadvantages of lanolin are that it is a common allergy and that it is a thick waxy substance that is difficult to apply.

Market Segmentation

The global xerosis market is categorized by therapy, cause, and end user.

The market is divided into therapeutic categories such as emollients, moisturizers, humidifiers, oils, and others.

The market has been classified into causes such as eczema, psoriasis, diabetes, hypothyroidism, aging, and others.

The market has been categorized by end users into hospitals, dermatological clinics, and home care.

Regional analysis.

The United States has the highest Xerosis market share because to increased medicine use and healthcare expenditure. The speedier market adoption of new technology and gadgets in the United States is another key driver of the Xerosis industry. Europe is the second largest market, owing to high disposable income and increased awareness. The Asia-Pacific area is predicted to have the biggest future potential, driven by China and India.

The Gulf nations, particularly Saudi Arabia and the United Arab Emirates, dominate the Middle East and Africa market. Africa's Xerosis market is predicted to develop moderately due to weak economic and political situations, as well as low healthcare penetration. Market Research Future's report on the Global Xerosis market includes extensive primary research as well as rigorous qualitative and quantitative analysis by various industry professionals and key opinion leaders to acquire a better understanding of the market and industry performance.

Key Players

Procter & Gamble, Alba Botanica, Avalon Organics, Johnson & Johnson Consumer Inc., Galderma Laboratories, Clarins, Unilever, Hempz, L'Oreal, Avon, Croda International Plc, Beiersdorf, Estee Lauder, United-Guardian, Inc., Dow Corning Corp., and others are the market leaders in Xerosis.

Product Code: MRFR/Pharma/2722-HCR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 RISING AWARENESS AND IMPROVED DIAGNOSIS
- 4.2.2 INNOVATIVE PRODUCT FORMULATIONS
- 4.2.3 RISE IN DISPOSABLE INCOME AND SPENDING ON SKINCARE
4.3 RESTRAINTS
- 4.3.1 SIDE EFFECTS ASSOCIATED WITH THE XEROSIS TREATMENT DRUGS
4.4 OPPORTUNITY
- 4.4.1 GROWING GERIATRIC POPULATION
- 4.4.2 INCREASE IN SELF-CARE PRACTICES FOR XEROSIS
- 4.4.3 ONGOING CLINICAL TRIALS AND UNIVERSITIES STUDIES

MARKET FACTOR ANALYSIS

4.5 PORTER'S FIVE FORCES MODEL
- 4.5.1 THREAT OF NEW ENTRANTS
- 4.5.2 BARGAINING POWER OF SUPPLIERS
- 4.5.3 THREAT OF SUBSTITUTES
- 4.5.4 BARGAINING POWER OF BUYERS
- 4.5.5 INTENSITY OF RIVALRY
4.6 IMPACT OF COVID-19 ON GLOBAL XEROSIS TREATMENT MARKET
4.7 EPIDEMIOLOGY ANALYSIS
4.8 MARKET TRENDS

5 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE

5.1 OVERVIEW
5.2 MEDICATION
- 5.2.1 ANTIHISTAMINES
- 5.2.2 CORTICOSTEROIDS
- 5.2.3 CALCINEURIN INHIBITORS
- 5.2.4 ANTI-INFLAMMATORY
- 5.2.5 IMMUNOMODULATORS
- 5.2.6 OTHERS
5.3 PERSONAL CARE PRODUCTS

6 GLOBAL XEROSIS TREATMENT MARKET, BY FORM

6.1 OVERVIEW
6.2 TABLETS
6.3 LOTION
6.4 CREAM
6.5 OINTMENT
6.6 SHOWER FOAMS
6.7 OTHERS

7 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP

7.1 OVERVIEW
7.2 PAEDIATRICS
7.3 ADULTS
7.4 ELDERLY

8 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER

8.1 OVERVIEW
8.2 MALE
8.3 FEMALE

9 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW
9.2 ONLINE
9.3 OFFLINE

10 GLOBAL XEROSIS TREATMENT MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 SPAIN
- 10.3.5 ITALY
- 10.3.6 RUSSIA
- 10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 SOUTH KOREA
- 10.4.5 MALAYSIA
- 10.4.6 THAILAND
- 10.4.7 INDONESIA
- 10.4.8 REST OF ASIA PACIFIC
10.5 SOUTH AMERICA
- 10.5.1 BRAZIL
- 10.5.2 MEXICO
- 10.5.3 ARGENTINA
- 10.5.4 REST OF SOUTH AMERICA
10.6 MIDDLE EAST AND AFRICA
- 10.6.1 GCC COUNTRIES
- 10.6.2 SOUTH AFRICA
- 10.6.3 REST OF MEA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS, 2023
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.1.1 PRODUCT LAUNCH

12 COMPANY PROFILES

12.1 AMGEN INC
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 PROCTER & GAMBLE
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGIES
12.3 UNILEVER
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 KEY STRATEGIES
12.4 PFIZER INC.
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 SWOT ANALYSIS
- 12.4.6 KEY STRATEGIES
12.5 CIPLA
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGIES
12.6 BAYER AG
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGY
12.7 JOHNSON & JOHNSON INC.
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 GALDERMA
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCT OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
12.9 DR. REDDY'S LABORATORIES LTD.
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCT OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 THORNTON & ROSS LTD.
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCT OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 KEY STRATEGIES

13 DATA CITATIONS

Product Code: MRFR/Pharma/2722-HCR

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
TABLE 2 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 3 GLOBAL XEROSIS TREATMENT MARKET, FOR MEDICATION, BY REGION, 2019-2032 (USD MILLION)
TABLE 4 GLOBAL XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 5 GLOBAL XEROSIS TREATMENT MARKET, FOR ANTIHISTAMINES, BY REGION, 2019-2032 (USD MILLION)
TABLE 6 GLOBAL XEROSIS TREATMENT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2019-2032 (USD MILLION)
TABLE 7 GLOBAL XEROSIS TREATMENT MARKET, FOR CALCINEURIN INHIBITORS, BY REGION, 2019-2032 (USD MILLION)
TABLE 8 GLOBAL XEROSIS TREATMENT MARKET, FOR ANTI-INFLAMMATORY, BY REGION, 2019-2032 (USD MILLION)
TABLE 9 GLOBAL XEROSIS TREATMENT MARKET, FOR IMMUNOMODULATORS, BY REGION, 2019-2032 (USD MILLION)
TABLE 10 GLOBAL XEROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
TABLE 11 GLOBAL XEROSIS TREATMENT MARKET, FOR PERSONAL CARE PRODUCTS, BY REGION, 2019-2032 (USD MILLION)
TABLE 12 GLOBAL XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 13 GLOBAL XEROSIS TREATMENT MARKET, FOR TABLETS, BY REGION, 2019-2032 (USD MILLION)
TABLE 14 GLOBAL XEROSIS TREATMENT MARKET, FOR LOTION, BY REGION, 2019-2032 (USD MILLION)
TABLE 15 GLOBAL XEROSIS TREATMENT MARKET, FOR CREAM, BY REGION, 2019-2032 (USD MILLION)
TABLE 16 GLOBAL XEROSIS TREATMENT MARKET, FOR OINTMENT, BY REGION, 2019-2032 (USD MILLION)
TABLE 17 GLOBAL XEROSIS TREATMENT MARKET, FOR SHOWER FOAMS, BY REGION, 2019-2032 (USD MILLION)
TABLE 18 GLOBAL XEROSIS TREATMENT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD MILLION)
TABLE 19 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 20 GLOBAL XEROSIS TREATMENT MARKET, FOR PAEDIATRICS, BY REGION, 2019-2032 (USD MILLION)
TABLE 21 GLOBAL XEROSIS TREATMENT MARKET, FOR ADULTS, BY REGION, 2019-2032 (USD MILLION)
TABLE 22 GLOBAL XEROSIS TREATMENT MARKET, FOR ELDERLY, BY REGION, 2019-2032 (USD MILLION)
TABLE 23 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 24 GLOBAL XEROSIS TREATMENT MARKET, FOR MALE, BY REGION, 2019-2032 (USD MILLION)
TABLE 25 GLOBAL XEROSIS TREATMENT MARKET, FOR FEMALE, BY REGION, 2019-2032 (USD MILLION)
TABLE 26 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 27 GLOBAL XEROSIS TREATMENT MARKET, FOR ONLINE, BY REGION, 2019-2032 (USD MILLION)
TABLE 28 GLOBAL XEROSIS TREATMENT MARKET, FOR OFFLINE, BY REGION, 2019-2032 (USD MILLION)
TABLE 29 GLOBAL XEROSIS TREATMENT MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 30 NORTH AMERICA XEROSIS TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 31 NORTH AMERICA XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 32 NORTH AMERICA XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 33 NORTH AMERICA XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 34 NORTH AMERICA XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 35 NORTH AMERICA XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 36 NORTH AMERICA XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 37 US: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 38 US: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 39 US: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 40 US: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 41 US: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 42 US: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 43 CANADA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 44 CANADA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 45 CANADA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 46 CANADA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 47 CANADA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 48 CANADA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 49 EUROPE XEROSIS TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 50 EUROPE: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 51 EUROPE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 52 EUROPE: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 53 EUROPE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 54 EUROPE: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 55 EUROPE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 56 GERMANY: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 57 GERMANY: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 58 GERMANY: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 59 GERMANY: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 60 GERMANY: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 61 GERMANY: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 62 FRANCE: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 63 FRANCE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 64 FRANCE: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 65 FRANCE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 66 FRANCE: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 67 FRANCE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 68 UK: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 69 UK: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 70 FRANCE: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 71 FRANCE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 72 FRANCE: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 73 FRANCE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 74 SPAIN: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 75 SPAIN: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 76 SPAIN: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 77 SPAIN: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 78 SPAIN: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 79 SPAIN: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 80 ITALY: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 81 ITALY: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 82 ITALY: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 83 ITALY: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 84 ITALY: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 85 ITALY: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 86 RUSSIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 87 RUSSIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 88 RUSSIA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 89 RUSSIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 90 RUSSIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 91 RUSSIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 92 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 93 REST OF EUROPE: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 94 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 95 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 96 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 97 REST OF EUROPE: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 98 ASIA PACIFIC XEROSIS TREATMENT MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 99 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 100 ASIA PACIFIC: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 101 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 102 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 103 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 104 ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 105 CHINA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 106 CHINA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 107 CHINA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 108 CHINA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 109 CHINA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 110 CHINA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 111 INDIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 112 INDIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 113 INDIA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 114 INDIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 115 INDIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 116 INDIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 117 JAPAN: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 118 JAPAN: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 119 JAPAN: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 120 JAPAN: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 121 JAPAN: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 122 JAPAN: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 123 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 124 SOUTH KOREA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 125 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 126 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 127 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 128 SOUTH KOREA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 129 MALAYSIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 130 MALAYSIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 131 MALAYSIA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 132 MALAYSIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 133 MALAYSIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 134 MALAYSIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 135 THAILAND: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 136 THAILAND: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 137 THAILAND: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 138 THAILAND: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 139 THAILAND: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 140 THAILAND: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 141 INDONESIA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 142 INDONESIA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 143 INDONESIA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 144 INDONESIA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 145 INDONESIA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 146 INDONESIA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 147 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 148 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 149 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 150 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 151 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 152 REST OF ASIA PACIFIC: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 153 SOUTH AMERICA XEROSIS TREATMENT MARKET, BY REGION, 2019-2032 (USD MILLION)
TABLE 154 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 155 SOUTH AMERICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 156 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 157 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 158 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 159 SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 160 BRAZIL: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 161 BRAZIL: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 162 BRAZIL: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 163 BRAZIL: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 164 BRAZIL: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 165 BRAZIL: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 166 MEXICO: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 167 MEXICO: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 168 MEXICO: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 169 MEXICO: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 170 MEXICO: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 171 MEXICO: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 172 ARGENTINA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 173 ARGENTINA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 174 ARGENTINA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 175 ARGENTINA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 176 ARGENTINA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 177 ARGENTINA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 178 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 179 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 180 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 181 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 182 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 183 REST OF SOUTH AMERICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 184 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY COUNTRY, 2019-2032 (USD MILLION)
TABLE 185 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 186 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 187 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 188 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 189 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 190 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 191 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 192 GCC COUNTRIES: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 193 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 194 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 195 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 196 GCC COUNTRIES: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 197 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 198 SOUTH AFRICA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 199 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 200 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 201 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 202 SOUTH AFRICA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 203 REST OF MEA: XEROSIS TREATMENT MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 204 REST OF MEA: XEROSIS TREATMENT MARKET, FOR MEDICATION, BY TYPE, 2019-2032 (USD MILLION)
TABLE 205 REST OF MEA: XEROSIS TREATMENT MARKET, BY FORM, 2019-2032 (USD MILLION)
TABLE 206 REST OF MEA: XEROSIS TREATMENT MARKET, BY AGE GROUP, 2019-2032 (USD MILLION)
TABLE 207 REST OF MEA: XEROSIS TREATMENT MARKET, BY GENDER, 2019-2032 (USD MILLION)
TABLE 208 REST OF MEA: XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2032 (USD MILLION)
TABLE 209 PUBLIC PLAYERS STOCK SUMMARY
TABLE 210 PRODUCT LAUNCH
TABLE 211 AMGEN INC.: PRODUCTS OFFERED
TABLE 212 AMGEN INC.: KEY DEVELOPMENTS
TABLE 213 PROCTER & GAMBLE: PRODUCTS OFFERED
TABLE 214 PROCTER & GAMBLE: KEY DEVELOPMENTS
TABLE 215 UNILEVER: PRODUCTS OFFERED
TABLE 216 PFIZER INC.: PRODUCTS OFFERED
TABLE 217 CIPLA: PRODUCTS OFFERED
TABLE 218 BAYER AG: PRODUCTS OFFERED
TABLE 219 JOHNSON & JOHNSON INC.: PRODUCTS OFFERED
TABLE 220 GALDERMA: PRODUCTS OFFERED
TABLE 221 DR. REDDY'S LABORATORIES LTD.: PRODUCTS OFFERED
TABLE 222 THORNTON & ROSS LTD.: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 GLOBAL XEROSIS MARKET: STRUCTURE
FIGURE 2 GLOBAL XEROSIS TREATMENT: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL XEROSIS TREATMENT MARKET
FIGURE 6 GLOBAL XEROSIS TREATMENT MARKET, TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
FIGURE 7 GLOBAL XEROSIS TREATMENT MARKET, BY TYPE, 2023 & 2032 (USD MILLION)
FIGURE 8 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY TYPE, 2023
FIGURE 9 GLOBAL XEROSIS TREATMENT MARKET, FORM SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
FIGURE 10 GLOBAL XEROSIS TREATMENT MARKET, BY FORM, 2023 & 2032 (USD MILLION)
FIGURE 11 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY FORM, 2023
FIGURE 12 GLOBAL XEROSIS TREATMENT MARKET, AGE GROUP SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
FIGURE 13 GLOBAL XEROSIS TREATMENT MARKET, BY AGE GROUP, 2023 & 2032 (USD MILLION)
FIGURE 14 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY AGE GROUP, 2023
FIGURE 15 GLOBAL XEROSIS TREATMENT MARKET, GENDER SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
FIGURE 16 GLOBAL XEROSIS TREATMENT MARKET, BY GENDER, 2023 & 2032 (USD MILLION)
FIGURE 17 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY GENDER, 2023
FIGURE 18 GLOBAL XEROSIS TREATMENT MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD MILLION)
FIGURE 19 GLOBAL XEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD MILLION)
FIGURE 20 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023
FIGURE 21 GLOBAL XEROSIS TREATMENT MARKET, BY REGION, 2023 & 2032 (USD MILLION)
FIGURE 22 GLOBAL XEROSIS TREATMENT MARKET SHARE (%), BY REGION, 2023
FIGURE 23 NORTH AMERICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 24 NORTH AMERICA XEROSIS TREATMENT MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 25 NORTH AMERICA XEROSIS TREATMENT MARKET SHARE (%), BY COUNTRY, 2023
FIGURE 26 EUROPE MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 27 EUROPE XEROSIS TREATMENT MARKET, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 28 EUROPE XEROSIS TREATMENT MARKET SHARE (%), BY COUNTRY, 2023
FIGURE 29 ASIA PACIFIC MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 30 ASIA PACIFIC: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 31 ASIA PACIFIC: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 32 SOUTH AMERICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 33 SOUTH AMERICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 34 SOUTH AMERICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 35 MIDDLE EAST AND AFRICA MARKET ANALYSIS: XEROSIS TREATMENT MARKET, 2019-2032 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA: XEROSIS TREATMENT MARKET SHARE, BY COUNTRY, 2023 (%)
FIGURE 38 GLOBAL XEROSIS TREATMENT MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023
FIGURE 39 COMPETITOR DASHBOARD: GLOBAL XEROSIS TREATMENT MARKET
FIGURE 40 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 41 AMGEN INC.: SWOT ANALYSIS
FIGURE 42 PROCTER & GAMBLE: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 43 PROCTER & GAMBLE: SWOT ANALYSIS
FIGURE 44 UNILEVER: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 45 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 46 PFIZER INC.: SWOT ANALYSIS
FIGURE 47 CIPLA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 48 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 49 BAYER AG: SWOT ANALYSIS
FIGURE 50 JOHNSON & JOHNSON INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 51 JOHNSON & JOHNSON INC.: SWOT ANALYSIS
FIGURE 52 GALDERMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 53 DR. REDDY'S LABORATORIES LTD.: FINANCIAL OVERVIEW SNAPSHOT